Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation

Inclusion Criteria: * Recipient of Single or Bilateral Lung Transplantation * Informed consent * Recipients who are able to receive Everolimus at week 3 after Lung Transplantation * women of childbearing potential must have a negative pregnancy test within 48 hours of enrolment * women of childbearing potential must use appropriate contraceptive method at enrolment, during the study and up to 8 weeks after the end of the study * donor must not have relevant pulmonary diseases * donor must have oxygen partial pressure higher than 300 mmHg at FiO 1.0 and positive end-expiratory pressure of 5 cm H2O. Exclusion Criteria: * systemic infection of the donor * donor: signs or symptoms of aspiration * donor: severe pulmonary injury or contusion * donor: malignant neoplasm of the lung * donor: HIV positive * recipients who receive immunosuppressive agents not used in this protocol * recipients who participated within 30 days before study start or are currently participating in another investigational drug trial * HIV positive recipient * systemic infection of the recipient * recipients of combined/ multiple transplantations * pregnancy of the recipient * recipients with signs/ Symptoms of impaired wound healing of the pulmonary anastomoses * recipients who are still on artificial respiration or who are not able to swallow tablets at week 3 after transplantation